2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
US
Venture Capital
| Venture Capital — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Latham & Watkins |
| Wilson Sonsini Goodrich & Rosati |
| Venture Capital — Recommended |
|---|
| Gunderson Dettmer |
| Hogan Lovells |
| Mintz Levin Cohn Ferris Glovsky and Popeo |
| Ropes & Gray |
| WilmerHale |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Dettmer, Scott | Financial & Corporate | Corporate, Venture Capital, Mergers & Acquisitions | Redwood City |
| Ehrlich, Timothy H | Financial & Corporate | Corporate, Venture Capital, Licensing & Collaboration, Mergers & Acquisitions | Boston |
| Gunderson, Robert | Financial & Corporate | Venture Capital, Mergers & Acquisitions | Redwood City |
| Hachigian, Jay | Financial & Corporate | Corporate, Venture Capital, Mergers & Acquisitions | Boston |
| Hatch, Marcia | Financial & Corporate | Venture Capital | Ann Arbor |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Financial & Corporate
Gunderson Dettmer is a highly reputable law firm with a strong reputation for assisting both emerging life sciences companies and funds in the venture capital space. In addition, their group of experienced practitioners advise a number of clients on licensing and collaboration agreements.
Timothy Ehrlich co-chairs the firm’s life sciences practice group representing both startups and established public life sciences companies throughout the entire corporate life cycle. In particular, Ehrlich has developed a niche for assisting emerging clients with venture capital financing, most recently advising Affinivax, a vaccine development company, and Akous, a gene therapy firm, in separate Series B rounds. Furthermore, Ehrlich served as lead counsel for Lyndra Therapeutics in its collaboration with Gilead Sciences to develop HIV therapies.
Based in the firm’s Ann Arbor offices but also operating from Silicon Valley, Marcia Hatch is a new addition to this year’s stars list. Hatch represents emerging life sciences clients as well as underwriters in a number of deals. Among her recent matters, Hatch represented Comet Therapeutics in its Series A financing as well as PACT Pharma with its Series C funding.